Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Cyclically Adjusted Revenue per Share: ¥2.89 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
62 GF Score
Price ¥8.07
GF Value ¥4.90
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted Revenue per Share?

Henan Taloph Pharmaceutical Stock Co SHSE:600222 +2.80% 62 Cyclically Adjusted Revenue per Share is ¥2.89 as of Mar. 2026. GuruFocus rates SHSE:600222 with a GF Score™ of 62/100 and a GF Value™ of ¥4.90 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Henan Taloph Pharmaceutical Stock Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.633. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥2.89 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Henan Taloph Pharmaceutical Stock Co's average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Henan Taloph Pharmaceutical Stock Co was 18.80% per year. The lowest was 0.80% per year. And the median was 3.90% per year.

As of today (2026-08-13), Henan Taloph Pharmaceutical Stock Co's current stock price is ¥8.07. Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥2.89. Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted PS Ratio of today is 2.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Henan Taloph Pharmaceutical Stock Co was 4.32. The lowest was 1.27. And the median was 2.18.


Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.07/2.89
=2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Henan Taloph Pharmaceutical Stock Co was 4.32. The lowest was 1.27. And the median was 2.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted Revenue per Share Related Terms


Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted Revenue per Share Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 2.72 2.67 2.73 2.86

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.75 2.77 2.81 2.86 2.89

SHSE:600222 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600222
62GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Taloph Pharmaceutical Stock Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Henan Taloph Pharmaceutical Stock Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.633/116.3033*116.3033
=0.633

Current CPI (Mar. 2026) = 116.3033.

Henan Taloph Pharmaceutical Stock Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.324 101.400 0.372
201609 0.452 102.400 0.513
201612 0.541 102.600 0.613
201703 0.413 103.200 0.465
201706 0.445 103.100 0.502
201709 0.556 104.100 0.621
201712 0.624 104.500 0.694
201803 0.542 105.300 0.599
201806 0.471 104.900 0.522
201809 0.463 106.600 0.505
201812 0.607 106.500 0.663
201903 0.479 107.700 0.517
201906 0.581 107.700 0.627
201909 0.538 109.800 0.570
201912 0.766 111.200 0.801
202003 0.778 112.300 0.806
202006 0.424 110.400 0.447
202009 0.577 111.700 0.601
202012 0.824 111.500 0.859
202103 0.745 112.662 0.769
202106 0.597 111.769 0.621
202109 0.649 112.215 0.673
202112 0.874 113.108 0.899
202203 0.743 114.335 0.756
202206 0.792 114.558 0.804
202209 0.771 115.339 0.777
202212 1.181 115.116 1.193
202303 0.989 115.116 0.999
202306 0.766 114.558 0.778
202309 0.801 115.339 0.808
202312 1.123 114.781 1.138
202403 0.895 115.227 0.903
202406 0.767 114.781 0.777
202409 0.746 115.785 0.749
202412 1.081 114.893 1.094
202503 0.591 115.116 0.597
202506 0.786 114.907 0.796
202509 0.767 115.471 0.773
202512 1.032 115.832 1.036
202603 0.633 116.303 0.633

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥2.89 mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Cyclically Adjusted Revenue per Share of ¥2.89 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors.
Is Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted Revenue per Share too high?
Henan Taloph Pharmaceutical Stock Co's current Cyclically Adjusted Revenue per Share is ¥2.89. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Henan Taloph Pharmaceutical Stock Co's Cyclically Adjusted Revenue per Share of ¥2.89 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. Henan Taloph Pharmaceutical Stock Co's current Cyclically Adjusted Revenue per Share is ¥2.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.90, compared to a current price of ¥8.07 — trading 64.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥2.89. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Cyclically Adjusted Revenue per Share is ¥2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥8.07 is trading 64.7% above its estimated GF Value™ of ¥4.90. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • Cyclically Adjusted Revenue per Share: ¥2.89
  • GF Value™: ¥4.90 vs. price of ¥8.07 (64.7% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
62GF Score

Get the complete analysis for SHSE:600222

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.07
Price
¥4.90
GF Value